Aptevo Therapeutics and Alligator Bioscience AB announced preliminary data from their Phase 1 trial evaluating ALG.APV-527, a first-in-class bispecific antibody, as monotherapy for multiple solid tumor types. The data, presented at the Society for Immunotherapy of Cancer on November 8, 2024, indicated that key trial endpoints of adequate exposure, safety, tolerability, and biological activity were successfully met.
The trial demonstrated encouraging signs of clinical benefit in patients with advanced solid tumors. A colon cancer patient achieved stable disease and remained on study for over six months, while a breast cancer patient remained on study for more than 11 months. These outcomes highlight the potential durability of response for ALG.APV-527.
Further analysis confirmed immune activation within the tumor microenvironment, supporting the drug's mechanism of action. More than half of the evaluable patients in the trial achieved stable disease, providing evidence of ALG.APV-527's biological activity and its potential as a therapeutic option for difficult-to-treat cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.